Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma
10.3779/j.issn.1009-3419.2024.102.28
- VernacularTitle:肺大细胞神经内分泌癌的治疗进展
- Author:
SUN JIAYI
1
;
JING YAWAN
;
TIAN PANWEN
;
LI WEIMIN
;
LI YALUN
Author Information
1. 610041 成都,四川大学华西医院呼吸与危重症医学科,呼吸和共病全国重点实验室,呼吸健康研究所,疾病分子网络前沿科学中心,精准医学中心/精准医学四川省重点实验室
- Keywords:
Large cell neuroendocrine carcinoma;
Molecular subtype;
Immune checkpoint inhibitors
- From:
Chinese Journal of Lung Cancer
2024;27(8):622-628
- CountryChina
- Language:Chinese
-
Abstract:
Large cell neuroendocrine carcinoma(LCNEC)of lung is a rare neuroendocrine carcinoma subtype with difficulty in early diagnosis and poor prognosis which is treated with standard strategies of small cell lung cancer and non-small cell lung cancer.In recent years,the precise types of LCNEC and its response to therapy have been identified by next-generation sequencing.Some researches have also found the correlation between different subtypes of LCNEC and the efficacy of chemotherapy regimens.However,there is no consensual agreement of its therapy.Recently,immune checkpoint inhibitors(ICIs)has provided a new option for LCNEC patients based on some retrospective research data and case reports.In this review,we aimed to summarize the epidemiological characteristics,standard therapy,the advances of molecular subtypes and clinical applications of ICIs of LCNEC,so as to provide optimal systemic clinical decision-making for LCNEC patients.
